Scientists have identified a new type of liver tumor
Release date: 2017-08-15 Source: Bio Valley Electric Cable Reel,Electric Hose Reel,Electric Garden Hose Reel,Retractable Electric Cord Reel NINGBO QIKAI ENVIRONMENTAL TECHNOLOGY CO.,LTD , https://www.water-hose-reel.com
Recently, a research report published in the international magazine Histopathology, researchers from Los Angeles Children's Hospital successfully identified a new type of rare childhood liver disease, related research or development of new treatments for later researchers. Liver disease offers new ideas. This study of hepatocellular carcinoma NOS (HEMNOS) is by far the largest of its kind, and HEMNOS is described as an entity with common hepatoblastoma (HB) and hepatocellular carcinoma (HCC). Characteristics.
The treatment of HEMNOS is generally very similar to the treatment of HCC. The researchers found that treatment of HEMNOS is similar to the treatment of hepatoblastoma subtypes, which can bring positive prognostic results to children; in the article, researchers from 2000 to 2016 During the year, 11 patients with liver cancer aged 4-15 years were studied. These patients were treated with HB-targeted chemotherapy and complete surgical resection. The prognosis of HEMNOS is currently considered to be poor. The treated patients survived and the disease was alleviated.
According to Leo Mascarenhas, MD, the patient's high survival rate also supports our assertion that HEMNOS is a subtype of hepatoblastoma, and if the tumor is not clearly defined, it is often impossible to treat the patient appropriately. The researchers performed a series of analyses to define specific tumor subtypes and pathological examinations of pre-chemotherapy specimens. The results showed that 6 tumor samples had HB and HCC tissue characteristics, and 4 samples had major HB histology. Characteristics and HCC-like histological features of the lesion, one of which has the histological characteristics of HB; the investigators believe that regardless of the initial diagnosis, each patient will benefit when hepatoblastoma therapy is used to treat HEMNOS.
In addition, the researchers also observed the expression of the telomerase gene (TERT), a repetitive DNA protein complex that is critical for the survival of cancer cells, with 9 patients in 11 patients. The expression of TERT has emerged; next, the researchers will conduct a more in-depth study to elucidate the genomic differences between HEMNOS and classical hepatoblastoma and hepatocellular carcinoma, in order to further clarify the incidence of this new type of tumor. Mechanisms and the development of new therapies provide some ideas and hopes.